Patents by Inventor Mark E. Schurdak

Mark E. Schurdak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS
    Publication number: 20240100018
    Abstract: Disclosed herein are methods of identifying a compound for treating or preventing an infection with an infectious microbe, such as a coronavirus, in a subject in need thereof. Also disclosed herein are compounds and compositions identified by said methods, and methods of use thereof.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 28, 2024
    Inventors: Mark E. SCHURDAK, Andreas VOGT, Andrew Michael STERN, Douglass Lansing TAYLOR, Fangyuan CHEN, Fen PEI, Hongying CHENG, Ivet BAHAR, Qingya SHI, Moshe ARDITI
  • Drug combinations for protecting against neuronal cell death
    Patent number: 11253594
    Abstract: Disclosed are compositions and methods for screening drugs that treat neurodegenerative disorders and methods of treating neurodegenerative orders with combinations of said drugs.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 22, 2022
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Andrew Michael Stern, Mark E. Schurdak
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
    Patent number: 11111253
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: September 7, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as Inhibitors of the STAT3 Pathway with Anti-Proliferative Activity
    Publication number: 20200339602
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 29, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • DRUG COMBINATIONS FOR PROTECTING AGAINST NEURONAL CELL DEATH
    Publication number: 20200129621
    Abstract: Disclosed are compositions and methods for screening drugs that treat neurodegenerative disorders and methods of treating neurodegenerative orders with combinations of said drugs.
    Type: Application
    Filed: July 9, 2018
    Publication date: April 30, 2020
    Inventors: Andrew Michael STERN, Mark E. SCHURDAK
  • 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
    Patent number: 10618914
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 14, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY
    Publication number: 20190100535
    Abstract: Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
    Type: Application
    Filed: January 15, 2016
    Publication date: April 4, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCTION
    Inventors: Donna M. Huryn, Peter Wipf, Jennifer Rubin Grandis, Matthew G. LaPorte, Paul A. Johnston, Mark E. Schurdak, Raffaele Colombo
  • Method of killing cancer cells
    Publication number: 20040180844
    Abstract: A method of killing cancer cells comprising inhibiting the function of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA; pharmaceutical compositions comprising an inhibitor of the same, and a method of detecting cellular hyperplasia.
    Type: Application
    Filed: March 10, 2003
    Publication date: September 16, 2004
    Inventors: Stephen W. Fesik, Donald N. Halbert, Randy E. Metzger, Jeffrey A. McDowell, Mark E. Schurdak, Susan E. Morgan-Lappe, Aparna V. Sarthy
  • Method of killing cancer cells
    Publication number: 20040180848
    Abstract: A method of killing cancer cells comprising inhibiting the function of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA; pharmaceutical compositions comprising an inhibitor of the same, and a method of detecting cellular hyperplasia.
    Type: Application
    Filed: March 9, 2004
    Publication date: September 16, 2004
    Inventors: Stephen W. Fesik, Donald N. Halbert, Randy E. Metzger, Jeffrey A. McDowell, Mark E. Schurdak, Susan E. Morgan-Lappe, Aparna V. Sarthy
  • Continuous format high throughput screening
    Patent number: 5976813
    Abstract: Continuous format high throughput screening (CF-HTS) using at least one porous matrix allows the pharmaceutical industry to simultaneously screen large numbers of chemical entities for a wide range of biological or biochemical activity. In addition, CF-HTS is useful to perform multi-step assays.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: November 2, 1999
    Assignee: Abbott Laboratories
    Inventors: Bruce A. Beutel, Mark E. Schurdak, Martin J. Voorbach, David J. Burns, Mary K. Joseph